Navigation Links
Sunesis Reports Financial Results for the Second Quarter 2009
Date:7/29/2009

NSOLIDATED STATEMENTS OF OPERATIONS Three months ended Six months ended June 30, June 30, ------------------ ------------------ 2009 2008 2009 2008 ---- ---- ---- ---- (Unaudited) (Unaudited) Revenue: Collaboration revenue-related party $1,500,000 $2,544,868 $1,500,000 $4,310,551 Collaboration revenue-other 12,500 46,372 25,000 583,872 License and other revenue 2,000,000 - 2,211,547 - --------- --------- --------- --------- Total revenues 3,512,500 2,591,240 3,736,547 4,894,423 Operating expenses: Research and development 3,448,685 8,262,604 7,712,836 17,005,499 General and administrative 1,994,903 3,235,061 4,349,916 6,501,190 Restructuring charges 532 4,876,746 1,863,393 5,197,520 --------- --------- --------- --------- Total operating expenses 5,444,120 16,374,411 13,926,145 28,704,209 --------- ---------- ---------- ---------- Loss from operations (1,931,620) (13,783,171) (10,189,598) (23,809,786) Interest income 6,000 269,385 18,812 729,797 Interest expense (375) (54,433) (987) (113,806) Other income (expense), net (20,952,469) (199) (21,070,126) 472 ----------- ----------- ----------- ------
'/>"/>
SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
2. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
3. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
4. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
5. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
6. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
7. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
8. Sunesis Pharmaceuticals to Report Financial Results for the First Quarter on May 8, 2008
9. Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
10. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
11. Sunesis to Present at Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... , March 5, 2015  In response to the ... Miami, FL on February 12, 2015. ... of strong financial health and their SUDOSCAN® devices have ... has indicated. Furthermore, Impeto prefers to have the courts decide ... are more than 40 articles written by Key Opinion ...
(Date:3/4/2015)... , March 4, 2015 In an article ... UPMC Center for Health Security review the clinical aspects ... be used as bioweapons. The article, "Clinical Management of ... on the website of the New England Journal ... Eric Toner , and Tom Inglesby—review the clinical ...
(Date:3/4/2015)... 2015 Research and Markets ( ... "Global Biologics and Biosimilars Industry Report 2015" ... The Global Biologics and Biosimilars Industry Report ... the current state of the biologics and biosimilars ... overview of the industry including definitions, classifications, applications ...
(Date:3/4/2015)... 4, 2015  BioClinica®, Inc., a leading ... today announced that clinical trial professionals representing ... its annual European User Conference in ... the use of its eClinical technologies to ... include: the Microsoft Office-Smart OnPoint CTMS; Express ...
Breaking Biology Technology:Impeto Medical Responds to Published Allegations by LD Technology LLC ("LD") 2Latest Clinical Information On Bioterrorism Threats 2Global Biologics and Biosimilars Industry Report 2015-2020 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 3
... - Treatment completed in Albuferon(R) Phase 3 trials; first Phase 3 data in ... December 2008 -, - Enrollment completed in LymphoStat-B(R) Phase 3 ... data in mid-2009 - ... - HGS updates financial guidance -, ROCKVILLE, Md., Nov. 6 Human Genome Sciences,Inc. (Nasdaq: ...
... SEATTLE, Nov. 6 /PRNewswire-FirstCall/ - Oncothyreon Inc. (NASDAQ:,ONTY) (TSX: ... and nine months ending September 30, 2008., Total ... three and nine,month periods ended September 30, 2008, compared ... in 2007. The increase in total revenue,for the nine ...
... Calif., Nov. 6 Accuray,Incorporated (Nasdaq: ARAY ... radiosurgery,announced today that in conjunction with its independent ... financial results for the first,quarter of fiscal 2009, ... allegations by a former employee of possible,improprieties in ...
Cached Biology Technology:Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments 2Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments 3Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments 4Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments 5Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments 6Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments 7Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments 8Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments 9Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments 10Oncothyreon reports third quarter 2008 financial results 2Oncothyreon reports third quarter 2008 financial results 3Oncothyreon reports third quarter 2008 financial results 4Oncothyreon reports third quarter 2008 financial results 5Accuray Postpones Release of First Quarter Fiscal 2009 Results 2
(Date:1/22/2015)... Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has announced the addition ... report to their offering. , The primary ... is who she/he is claiming to be, and for this ... physical characteristics, such as fingerprint, hand or palm print, iris, ...
(Date:1/22/2015)... , Jan. 13, 2015 /PRNewswire/ - Today, FindBiometrics, the leading source ... launch of its new website design. "When we ... infancy", says Peter O,Neill , founder and CEO of ... industry needs involvement from the key players on a very ...
(Date:1/22/2015)... 2015 Technology Showcase, Hall E -   EyeLock Inc. ... announced it will showcase its EyeLock ID technology integrated in ... of Energy,s Oak Ridge National Laboratory (ORNL) at ... iris identity authentication technology is being used to validate the ...
Breaking Biology News(10 mins):Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3
... impact on levels of carbon dioxide in the Earth,s atmosphere ... that includes starfish and sea urchin has been significantly underestimated. ... sink into account," says Mario Lebrato, lead author of the ... National Oceanography Centre, Southampton (NOCS) and affiliated with the University ...
... in Atlantic puffins could be due to worsening conditions within ... scientific journal Marine Biology . The study used geolocation ... Nature Reserve, home to the largest colony of puffins in ... May has declined by 30% in recent years. The ...
... WORCESTER, Mass. A collaboration between the University ... Medicine at Tufts University and the Broad Institute at ... locus on canine chromosome 7 which coincides with an ... findings, published in the January 2010 edition of ...
Cached Biology News:Echinoderms contribute to global carbon sink 2Where do puffins go in the winter? 2Canine compulsive disorder gene identified 2
DDO Immunogen: DDO (NP_003640, 270 a.a. ~ 370 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Yersinia pestis...
Insect Cell Lysis Buffer 50 ml...
Rabbit polyclonal to Orexin Prepro ( Abpromise for all tested applications). entrezGeneID: 3060 SwissProtID: O43612...
Biology Products: